Sartorius Stedim Biotech (OTCMKTS:SDMHF) Trading Up 1.7% – What’s Next?

Shares of Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF) shot up 1.7% during mid-day trading on Friday . The stock traded as high as $214.65 and last traded at $214.65. 46 shares were traded during trading, a decline of 97% from the average session volume of 1,797 shares. The stock had previously closed at $211.00.

Analyst Ratings Changes

Several equities analysts recently weighed in on SDMHF shares. The Goldman Sachs Group lowered Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a research note on Monday, January 12th. Barclays reiterated an “overweight” rating on shares of Sartorius Stedim Biotech in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Sartorius Stedim Biotech Stock Performance

The firm’s 50-day moving average is $235.98 and its two-hundred day moving average is $225.40.

Sartorius Stedim Biotech Company Profile

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.